
Opinion|Videos|September 27, 2024
Treatment Landscape for Transplant-Eligible Patients with NDMM
Panelists discuss how the current first-line treatment options for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) typically involve combination therapies including proteasome inhibitors, immunomodulatory drugs, and steroids.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Provide a brief overview of first-line treatment options currently available for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM).
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Removes Black Boxed Warning From Hormone Therapies for Menopause
2
Pharmacist-Led Interventions Yield Long-Term HbA1c, Blood Pressure Improvements in Minority Groups
3
Major Review Finds No Link Between Maternal Tylenol and Autism Spectrum Disorder, ADHD
4
New Drug Demonstrates Major Triglyceride Reductions and Liver Fat Improvements in Phase 2 Trial
5
















































































































































































































